Clinical Report: AAD Names New Vice President, Board Members
Overview
The American Academy of Dermatology (AAD) has appointed Cyndi J. Yag-Howard, MD, FAAD, as its 2024-2025 Vice President and introduced five new board members. This leadership transition follows the conclusion of the 2024 AAD Annual Meeting.
Background
Leadership changes within professional organizations like the AAD are significant. The AAD plays a crucial role in advancing dermatologic care through education, advocacy, and the development of clinical guidelines.
Data Highlights
No numerical or trial data available in the source material.
Key Findings
- Cyndi J. Yag-Howard, MD, FAAD, is the new Vice President of the AAD for 2024-2025.
- Five new board members have been appointed to the AAD Board of Directors.
- The new board members will serve four-year terms starting from the conclusion of the 2024 AAD Annual Meeting.
- Dr. Yag-Howard is an Affiliate Clinical Professor of Dermatology at the University of South Florida Morsani College of Medicine.
- New board member roles include leadership positions in various dermatology-related committees and organizations.
Clinical Implications
The appointment of new leadership within the AAD is a notable event for the organization.
Conclusion
The recent leadership appointments within the AAD are a key development for the organization.
Related Resources & Content
- American Academy of Dermatology, AAD 2024: AAD Names New Vice President, Board Members
- conexiant — AAD 2024: AAD Welcomes Seemal R. Desai, MD, FAAD, as President
- The ASCO Post — New AACR President-Elect and Board Members Announced
- The ASCO Post — New AACR President-Elect and Board Members Announced
- The ASCO Post — New AACR President-Elect and Board Members Announced
- AAD Welcomes Seemal R. Desai, MD, FAAD, as President
- American Academy of Dermatology issues first-ever pediatric atopic dermatitis guidelines, highlighting prevention strategies and effective treatments
- Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
